References

1. Weinberger DR, Laruelle M: Neurochemical and neuropharmacologic imaging in schizophrenia, in Neuropsychopharmacology: The Fifth Generation of Progress. Edited by Davis KL, Charney D, Coyle JT, Nemeroff C. Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp 833-855

2. Bertolino A, Weinberger DR: Proton magnetic resonance spectroscopy in schizophrenia. Eur J Radiol 1999; 30(2):132-41

3. Marenco S, Bertolino A, Weinberger DR: MR proton spectroscopy, in Schizophrenia: from neuroimaging to neuroscience, vol 1. Edited by Lawrie SM, Johnstone EC, Weinberger DR. Oxford, UK, Oxford University Press, 2004, pp 73-92

4. Keshavan MS, Stanley JA, Pettegrew JW: Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings—part II. Biol Psychiatry 2000; 48(5):369-80

5. Stanley JA, Pettegrew JW, Keshavan MS: Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings—part I. Biol Psychiatry 2000; 48(5):357-68

6. Duyn JH, Gillen J, Sobering G, van Zijl PC, Moonen CT: Multisection proton MR spectroscopic imaging of the brain. Radiology 1993; 188(1):277-82

7. van Der Veen JW, Weinberger DR, Tedeschi G, Frank JA, Duyn JH: Proton MR spectroscopic imaging without water suppression. Radiology 2000; 217(1):296-300

8. Weinberger DR: Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry 1999; 45(4):395-402

9. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK, Berman KF, Goldberg TE: Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50(11):825-44

10. Bertolino A, Nawroz S, Mattay VS, Barnett AS, Duyn JH, Moonen CT, Frank JA, Tedeschi G, Weinberger DR: Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am J Psychiatry 1996; 153(12):1554-63

11. Bertolino A, Callicott JH, Nawroz S, Mattay VS, Duyn JH, Tedeschi G, Frank JA, Weinberger DR: Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia. Neuropsychopharmacology 1998; 18(1):1-9

12. Bertolino A, Kumra S, Callicott JH, Mattay VS, Lestz RM, Jacobsen L, Barnett IS, Duyn JH, Frank JA, Rapoport JL, Weinberger DR: Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. Am J Psychiatry 1998; 155(10):1376-83

13. Callicott JH, Egan MF, Bertolino A, Mattay VS, Langheim FJ, Frank JA, Weinberger DR: Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype. Biol Psychiatry 1998; 44(10):941-50

14. Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJ, Weinberger DR: Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. Am J Psychiatry 2000; 157(10):1646-51

15. Lewis DA, Lieberman JA: Catching up on schizophrenia: natural history and neurobiology. Neuron 2000; 28(2):325-34

16. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, Weinberger DR: The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 2001; 49(1):39-46

17. Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JA, Berman KF, Weinberger DR: Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am J Psychiatry 2000; 157(1):26-33

18. Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, Goldberg TE, Weinberger DR: Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000; 10(11):1078-92

19. Winterer G, Weinberger DR: Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 2004; 27(11):683-90

20. Bertolino A, Breier A, Callicott JH, Adler C, Mattay VS, Shapiro M, Frank JA, Pickar D, Weinberger DR: The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 2000; 22(2):125-32

21. Bertolino A, Knable MB, Saunders RC, Callicott JH, Kolachana B, Mattay VS, Bachevalier J, Frank JA, Egan M, Weinberger DR: The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol Psychiatry 1999; 45(6):660-7

22. Lipska BK, Jaskiw GE, Weinberger DR: Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 1993; 9(1):67-75

23. Saunders RC, Kolachana BS, Bachevalier J, Weinberger DR: Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature 1998; 393(6681):169-71

24. Lipska BK, Weinberger DR: To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000; 23(3):223-39

25. Bertolino A, Roffman JL, Lipska BK, van Gelderen P, Olson A, Weinberger DR: Reduced N-acetylaspartate in prefrontal cortex of adult rats with neonatal hippocampal damage. Cereb Cortex 2002; 12(9):983-90

26. Bertolino A, Saunders RC, Mattay VS, Bachevalier J, Frank JA, Weinberger DR: Altered development of prefrontal neurons in rhesus monkeys with neonatal mesial temporo-limbic lesions: a proton magnetic resonance spectroscopic imaging study. Cereb Cortex 1997; 7(8):740-8

27. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, Lu B, Weinberger DR: The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112(2):257-69

28. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, Mattay VS, Bertolino A, Hyde TM, Shannon-Weickert C, Akil M, Crook J, Vakkalanka RK, Balkissoon R, Gibbs RA, Kleinman JE, Weinberger DR: Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A 2004; 101(34):12604-9

29. Steele SU, Marenco S, Barnett AS, van der Veen JW, Egan MF, Weinberger DR: GRM3 genotype is associated with reduced N-acetyl aspartate levels in the frontal cortex: A partial replication. Biological Psychiatry 2004; 55:167S-167S

Unraveling Alzheimers Disease

Unraveling Alzheimers Disease

I leave absolutely nothing out! Everything that I learned about Alzheimer’s I share with you. This is the most comprehensive report on Alzheimer’s you will ever read. No stone is left unturned in this comprehensive report.

Get My Free Ebook


Post a comment